 WESTMER, Colo., March 18, 2021 GLOBE NEWSWIRE -- ARCA biopharma, Inc. Nasdaq: ABIO, a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update. 